Hepion insider buys 12.5M warrants at $0.06

Hepion Pharmaceuticals, Inc. (HEPA) insider Vincent S. LoPriore, Executive Chairman and director, reported the purchase of 12,500,000 warrants on September 3, 2026, indirectly through Gravitas Capital LP.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) insider Vincent S. LoPriore, Executive Chairman and director, reported the purchase of 12,500,000 warrants on September 3, 2026, indirectly through Gravitas Capital LP. These warrants are exercisable into 12,500,000 shares of common stock at $0.06 per share, expiring September 3, 2031, and become exercisable only upon stockholder approval of an increase in authorized common shares, bringing his indirectly held warrants to 22,500,000.

Insider Trade Summary

Net Buyer: 12,500,000 shares

Net Buy 1 txn

Insider LoPriore Vincent S

Role Executive Chairman

Bought 12,500,000 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Warrants F1, F2	12,500,000	$0.00	$0.00

Holdings After Transaction: Warrants — 22,500,000 contracts (Indirect, By Gravitas Capital LP)

Footnotes (2)

1. F1. Warrant is only exercisable upon stockholder approval of an increase in the authorized shares of the Company's Common Stock.
2. F2. Mr. LoPriore is the Managing Member of Gravitas Capital LP and in such capacity has the right to vote and dispose of the securities held by such entity.

Key Figures

Warrants purchased: 12,500,000 warrants Exercise price: $0.06 per share Underlying shares: 12,500,000 shares +2 more

5 metrics

Warrants purchased 12,500,000 warrants Derivative purchase reported for September 3, 2026

Exercise price $0.06 per share Exercise price of warrants into Hepion common stock

Underlying shares 12,500,000 shares Common shares underlying the newly purchased warrants

Total warrants after transaction 22,500,000 warrants Indirectly held by Gravitas Capital LP after the transaction

Warrant expiration date September 3, 2031 Expiration date of the reported warrants

Key Terms

Warrants, exercise price, authorized shares, indirectly owned, +1 more

5 terms

Warrants financial

"Warrants are exercisable into common stock at a set price before expiration"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"The warrants are exercisable at an exercise price of $0.06 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

authorized shares financial

"Warrant is only exercisable upon stockholder approval of an increase in the authorized shares"

Authorized shares are the maximum number of shares a company is allowed to issue according to its official plan. Think of it as a company’s set limit on how many pieces of its ownership it can distribute to investors. This number helps investors understand the potential for future growth or change in the company's ownership structure.

indirectly owned financial

"The warrants are indirectly owned through Gravitas Capital LP"

expiration date financial

"The warrants carry an expiration date of September 3, 2031"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HEPA insider Vincent S. LoPriore report on this Form 4?

He reported buying 12,500,000 warrants on September 3, 2026, indirectly through Gravitas Capital LP. Each warrant is exercisable into one share of Hepion Pharmaceuticals, Inc. common stock at an exercise price of $0.06 per share, expiring September 3, 2031.

How many HEPA warrants does Vincent S. LoPriore hold after this transaction?

After the reported transaction, Vincent S. LoPriore indirectly holds 22,500,000 warrants linked to Hepion Pharmaceuticals, Inc. common stock, held through Gravitas Capital LP, where he is the Managing Member with authority to vote and dispose of the securities.

Are the newly acquired HEPA warrants immediately exercisable?

No. The filing states the warrant is only exercisable upon stockholder approval of an increase in the authorized shares of Hepion Pharmaceuticals, Inc. common stock, meaning exercise is contingent on that stockholder action.

What is the exercise price and expiration date of the HEPA warrants reported?

The warrants have an exercise price of $0.06 per share and an expiration date of September 3, 2031. Each warrant is exercisable for one share of Hepion Pharmaceuticals, Inc. common stock if the exercisability condition is met.

Is the HEPA Form 4 transaction under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan. There is no footnote indicating that the September 3, 2026 warrant purchase was effected pursuant to a Rule 10b5-1 or other pre-arranged trading plan.

How are the HEPA securities in this Form 4 held by Vincent S. LoPriore?

The warrants are reported as indirectly owned "By Gravitas Capital LP." A footnote explains that Vincent S. LoPriore is the Managing Member of Gravitas Capital LP and, in that capacity, has the right to vote and dispose of the securities held by the entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:30 AM Accepted by SEC EDGAR 09/14/2026 - 06:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LoPriore Vincent S

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.06	09/03/2026		P		12,500,000		09/03/2026(1)	09/03/2031	Common Stock	12,500,000	$0	22,500,000	I	By Gravitas Capital LP(2)

Explanation of Responses:

1. Warrant is only exercisable upon stockholder approval of an increase in the authorized shares of the Company's Common Stock.

2. Mr. LoPriore is the Managing Member of Gravitas Capital LP and in such capacity has the right to vote and dispose of the securities held by such entity.

	/s/ Vincent S. LoPriore	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)